Drug Profile

Certoparin sodium - Novartis

Alternative Names: Certoparin; Mono-Embolex; Sandoparin; Sandoparine; Troparin

Latest Information Update: 10 Sep 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novartis
Class Antithrombotics; Low molecular weight heparins
Mechanism of Action Factor Xa inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Marketed Deep vein thrombosis; Pulmonary embolism; Thromboembolism

Most Recent Events

07 Sep 2020 Mylan enteres into an agreement with Aspen to acquire Certoparin sodium from Aspen in Europe
06 Sep 2015 Launched for Thromboembolism (Prevention) in India (SC) before September 2015
03 Feb 2015 Launched for Thromboembolism (Prevention) in Austria (SC) before February 2015

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com